Main content

    Lymphoma Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at

    Active Trials

    Title: Phase II Study of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non Hodgkin's Lymphoma
    Description: This study is to see how well giving lenalidomide together with rituximab works in treating patients with previously untreated indolent Non Hodgkin's Lymphoma
    Investigator (Santa Rosa): Peter Brett, MD
    Eligibility: Subjects, 18 y/o and older, with previously untreated, histologically confirmed indolent lymphoma including follicle cell lymphoma, WHO classification, grade I or II, and marginal zone lymphoma
    Status: Active and open to enrollment
    Contact (Santa Rosa): Christina DeVisser, 707-576-4739, Email: about Study UCD Lymphoma

    Title: EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
    Description: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with histologically documented solid tumors or histologically confirmed diagnosis of lymphoma that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472 Email: about Study EAY131 NCI-MATCH

    • Updated Sept. 2, 2015

    Back to top